Adjuvant topical treatment with imiquimod 5% after excisional surgery for VIN 2/3

M. Gentile, P. Bianchi, F. Sesti, F. Sopracordevole, A. Biamonti, P. Scirpa, M. Schimberni, G. Cozza, R. Marziani, G. Di Martino, A. Catalano, G. N. Milazzo, M. Zinna, D. Caserta, A. Frega

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

OBJECTIVE: Vulvar intraepithelial neoplasia (VIN) is a premalignant lesion of the vulva. The incidence of VIN is increasing. The surgery is currently the gold standard therapy for VIN, but Imiquimod could be a completion to surgery. The aim of this study is to compare the overall complete response, the recurrence rate and the risk factors for recurrence among two groups of patients: women with high grade VIN underwent surgery and patients treated with surgery plus Imiquimod.

PATIENTS AND METHODS: 80 patients with histologically diagnosed VIN 2/3 were enrolled in this prospective study. Our patients were divided into two groups: 40 women underwent surgery (A) and 40 patients were treated with surgery plus Imiquimod (B). All women had a 5-year follow-up. Recurrence rate and complete response were evaluated. The following patients' characteristics were analyzed: smoke, multifocal disease, multicentric disease, degree of the lesion.

RESULTS: In the group A recurrence rate was 44.8%, in the group B it was 48.4%. In both groups the presence of multifocal lesions (p = 0.02) and VIN 3 (p = 0.006) before treatment was associated with a higher risk of recurrence.

CONCLUSIONS: This study found that surgery remains the principal approach for VIN with regard to relapse and complete response since the treatment with Imiquimod associated with surgery didn't show a lower recurrence rate. Although the surgical treatments remain the best therapeutic option for VIN with regard to recurrence and overall complete response, the combined therapy seems to be an interesting modality, but further studies are needed.

Original languageEnglish
Pages (from-to)2949-2952
Number of pages4
JournalEuropean Review for Medical and Pharmacological Sciences
Volume18
Issue number19
Publication statusPublished - Oct 1 2014

Fingerprint

imiquimod
Recurrence
Neoplasms
Therapeutics
Vulva
Smoke

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gentile, M., Bianchi, P., Sesti, F., Sopracordevole, F., Biamonti, A., Scirpa, P., ... Frega, A. (2014). Adjuvant topical treatment with imiquimod 5% after excisional surgery for VIN 2/3. European Review for Medical and Pharmacological Sciences, 18(19), 2949-2952.

Adjuvant topical treatment with imiquimod 5% after excisional surgery for VIN 2/3. / Gentile, M.; Bianchi, P.; Sesti, F.; Sopracordevole, F.; Biamonti, A.; Scirpa, P.; Schimberni, M.; Cozza, G.; Marziani, R.; Di Martino, G.; Catalano, A.; Milazzo, G. N.; Zinna, M.; Caserta, D.; Frega, A.

In: European Review for Medical and Pharmacological Sciences, Vol. 18, No. 19, 01.10.2014, p. 2949-2952.

Research output: Contribution to journalArticle

Gentile, M, Bianchi, P, Sesti, F, Sopracordevole, F, Biamonti, A, Scirpa, P, Schimberni, M, Cozza, G, Marziani, R, Di Martino, G, Catalano, A, Milazzo, GN, Zinna, M, Caserta, D & Frega, A 2014, 'Adjuvant topical treatment with imiquimod 5% after excisional surgery for VIN 2/3', European Review for Medical and Pharmacological Sciences, vol. 18, no. 19, pp. 2949-2952.
Gentile, M. ; Bianchi, P. ; Sesti, F. ; Sopracordevole, F. ; Biamonti, A. ; Scirpa, P. ; Schimberni, M. ; Cozza, G. ; Marziani, R. ; Di Martino, G. ; Catalano, A. ; Milazzo, G. N. ; Zinna, M. ; Caserta, D. ; Frega, A. / Adjuvant topical treatment with imiquimod 5% after excisional surgery for VIN 2/3. In: European Review for Medical and Pharmacological Sciences. 2014 ; Vol. 18, No. 19. pp. 2949-2952.
@article{90db55dc5f4c4cefaea3a5675f329886,
title = "Adjuvant topical treatment with imiquimod 5{\%} after excisional surgery for VIN 2/3",
abstract = "OBJECTIVE: Vulvar intraepithelial neoplasia (VIN) is a premalignant lesion of the vulva. The incidence of VIN is increasing. The surgery is currently the gold standard therapy for VIN, but Imiquimod could be a completion to surgery. The aim of this study is to compare the overall complete response, the recurrence rate and the risk factors for recurrence among two groups of patients: women with high grade VIN underwent surgery and patients treated with surgery plus Imiquimod.PATIENTS AND METHODS: 80 patients with histologically diagnosed VIN 2/3 were enrolled in this prospective study. Our patients were divided into two groups: 40 women underwent surgery (A) and 40 patients were treated with surgery plus Imiquimod (B). All women had a 5-year follow-up. Recurrence rate and complete response were evaluated. The following patients' characteristics were analyzed: smoke, multifocal disease, multicentric disease, degree of the lesion.RESULTS: In the group A recurrence rate was 44.8{\%}, in the group B it was 48.4{\%}. In both groups the presence of multifocal lesions (p = 0.02) and VIN 3 (p = 0.006) before treatment was associated with a higher risk of recurrence.CONCLUSIONS: This study found that surgery remains the principal approach for VIN with regard to relapse and complete response since the treatment with Imiquimod associated with surgery didn't show a lower recurrence rate. Although the surgical treatments remain the best therapeutic option for VIN with regard to recurrence and overall complete response, the combined therapy seems to be an interesting modality, but further studies are needed.",
author = "M. Gentile and P. Bianchi and F. Sesti and F. Sopracordevole and A. Biamonti and P. Scirpa and M. Schimberni and G. Cozza and R. Marziani and {Di Martino}, G. and A. Catalano and Milazzo, {G. N.} and M. Zinna and D. Caserta and A. Frega",
year = "2014",
month = "10",
day = "1",
language = "English",
volume = "18",
pages = "2949--2952",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "19",

}

TY - JOUR

T1 - Adjuvant topical treatment with imiquimod 5% after excisional surgery for VIN 2/3

AU - Gentile, M.

AU - Bianchi, P.

AU - Sesti, F.

AU - Sopracordevole, F.

AU - Biamonti, A.

AU - Scirpa, P.

AU - Schimberni, M.

AU - Cozza, G.

AU - Marziani, R.

AU - Di Martino, G.

AU - Catalano, A.

AU - Milazzo, G. N.

AU - Zinna, M.

AU - Caserta, D.

AU - Frega, A.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - OBJECTIVE: Vulvar intraepithelial neoplasia (VIN) is a premalignant lesion of the vulva. The incidence of VIN is increasing. The surgery is currently the gold standard therapy for VIN, but Imiquimod could be a completion to surgery. The aim of this study is to compare the overall complete response, the recurrence rate and the risk factors for recurrence among two groups of patients: women with high grade VIN underwent surgery and patients treated with surgery plus Imiquimod.PATIENTS AND METHODS: 80 patients with histologically diagnosed VIN 2/3 were enrolled in this prospective study. Our patients were divided into two groups: 40 women underwent surgery (A) and 40 patients were treated with surgery plus Imiquimod (B). All women had a 5-year follow-up. Recurrence rate and complete response were evaluated. The following patients' characteristics were analyzed: smoke, multifocal disease, multicentric disease, degree of the lesion.RESULTS: In the group A recurrence rate was 44.8%, in the group B it was 48.4%. In both groups the presence of multifocal lesions (p = 0.02) and VIN 3 (p = 0.006) before treatment was associated with a higher risk of recurrence.CONCLUSIONS: This study found that surgery remains the principal approach for VIN with regard to relapse and complete response since the treatment with Imiquimod associated with surgery didn't show a lower recurrence rate. Although the surgical treatments remain the best therapeutic option for VIN with regard to recurrence and overall complete response, the combined therapy seems to be an interesting modality, but further studies are needed.

AB - OBJECTIVE: Vulvar intraepithelial neoplasia (VIN) is a premalignant lesion of the vulva. The incidence of VIN is increasing. The surgery is currently the gold standard therapy for VIN, but Imiquimod could be a completion to surgery. The aim of this study is to compare the overall complete response, the recurrence rate and the risk factors for recurrence among two groups of patients: women with high grade VIN underwent surgery and patients treated with surgery plus Imiquimod.PATIENTS AND METHODS: 80 patients with histologically diagnosed VIN 2/3 were enrolled in this prospective study. Our patients were divided into two groups: 40 women underwent surgery (A) and 40 patients were treated with surgery plus Imiquimod (B). All women had a 5-year follow-up. Recurrence rate and complete response were evaluated. The following patients' characteristics were analyzed: smoke, multifocal disease, multicentric disease, degree of the lesion.RESULTS: In the group A recurrence rate was 44.8%, in the group B it was 48.4%. In both groups the presence of multifocal lesions (p = 0.02) and VIN 3 (p = 0.006) before treatment was associated with a higher risk of recurrence.CONCLUSIONS: This study found that surgery remains the principal approach for VIN with regard to relapse and complete response since the treatment with Imiquimod associated with surgery didn't show a lower recurrence rate. Although the surgical treatments remain the best therapeutic option for VIN with regard to recurrence and overall complete response, the combined therapy seems to be an interesting modality, but further studies are needed.

UR - http://www.scopus.com/inward/record.url?scp=84930185874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930185874&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 2949

EP - 2952

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 19

ER -